semaglutide glp-1 medication GLP-1s Diabetes advocacy group discourages use

Obese for sure you qualify, but also taking into consideration any comorbidities that you have like high cholesterol, high blood pressure, sleep apnea, PCOS. Given that more than 40% of American adults meet the clinical definition of obesity, a lot of people asking whether they qualify already do

Patients who combine GLP-1 therapy with dietary changes and increased physical activity typically experience faster and more pronounced weight loss

For a drug to passively diffuse through this layer, it typically needs to be: Small in molecular size Lipophilic (fat-soluble) However, GLP-1 molecules: Are too large and hydrophilic Cannot naturally penetrate the skin barrier Even if GLP-1 patches claim to have GLP-1 drugs, the molecules cannot pass through the skin barrier without support

In clinical trials, tirzepatide demonstrated significant reductions in hemoglobin A1c levels (up to 2.5% reduction in SURPASS diabetes trials) and body weight (up to 20% reduction in SURMOUNT obesity trials) compared to placebo and other medications

The FDA has warned consumers about dosing errors, questionable ingredients, and adverse events tied to some of these products